NHLBI Strategic Visioning

NHLBI Strategic Visioning

NHLBI Clinical Trials

Trustworthy guidelines should be based on a systematic evidence review, developed by panel of multidisciplinary experts, provide a clear explanation of the logical relationships between alternative care options and health outcomes, and provide ratings of both the quality of evidence and the strength of the recommendations.

NHLBI Systematic Evidence Reviews in development.

Inside NHLBI

Researcher Brings Medicine One Step Closer to Widely Available Cure for Sickle Cell Disease

Gary H. Gibbons
September 2, 2014
From the use of antibiotics to prevent and treat infections in children with sickle cell disease to the FDA approval of the drug hydroxyurea, researchers have made steady progress during the last few decades in improving the lives of individuals with sickle cell disease. Yet still, a widely available cure has remained just out of reach. Now, work from a team of researchers at the National Institutes of Health, including NHLBI's Dr. John Tisdale may open the door to reversing sickle cell disease in more patients.
View full message

View all Director's messages

Subscribe to receive "What's New" by email: